Sold as Lexiva. Every FDA application for this active ingredient: 2 branded and 3 generic.
As of Nov 15, 2026, FDA lists 5 applications for Fosamprenavir Calcium (sold as Lexiva), first approved Oct 20, 2003, with 3 new uses approved and 0 published complete response letters.
| Fosamprenavir Calcium | Part D | $1.0M | -24% | 120 |
| Lexiva | Part D | $0K | -100% | 0 |
| Oral Fosamprenavir for GERDRefractory Gastroesophageal Reflux Disease, Gastroesophageal Reflux Disease · Medical College of Wisconsin | Phase 2 | Not yet recruiting | Nov 25, 2024 |
| Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)HIV-1-infection · Gilead Sciences | Phase 2 / Phase 3 | Active, not recruiting | Aug 16, 2022 |
| Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme ReductionLaryngopharyngeal Reflux · Medical College of Wisconsin | Phase 2 | Recruiting | May 12, 2020 |
| Oct 20, 2003 | LexivaNDA 21548 · New active ingredient | Viiv Hlthcare | 31 | Discontinued |
| Jun 14, 2007 | LexivaNDA 22116 · New dosage form | Viiv Hlthcare | 15 | Discontinued |
| Apr 15, 2016 | Fosamprenavir CalciumANDA 204060 | Mylan | 2 | Marketed |
| Nov 20, 2019 | Fosamprenavir CalciumANDA 204024 | Sun Pharm | 1 | Marketed |
| — | Fosamprenavir CalciumANDA 204130 | Lupin Ltd | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Mylan